| scholarly article | Q13442814 |
| P50 | author | Ana Ruiz-Saenz | Q64681921 |
| P2093 | author name string | Mark M Moasser | |
| P2860 | cites work | Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 | Q24633878 |
| The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation | Q24678674 | ||
| Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer | Q27013852 | ||
| Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab | Q27640593 | ||
| Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3 | Q27646596 | ||
| An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin | Q27679463 | ||
| An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase | Q27682355 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. | Q27851451 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy | Q39960692 | ||
| Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. | Q40144433 | ||
| Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. | Q40596817 | ||
| Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B | Q40623032 | ||
| The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. | Q40685410 | ||
| Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells | Q41913443 | ||
| Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia | Q43899710 | ||
| Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth | Q44120544 | ||
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial | Q45073151 | ||
| Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization. | Q45923393 | ||
| Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery | Q46059342 | ||
| Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma | Q46684059 | ||
| Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study | Q47604705 | ||
| Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer | Q48252174 | ||
| First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. | Q51170722 | ||
| DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. | Q54204362 | ||
| Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. | Q54791338 | ||
| Cellular Adaptive Immune System Plays a Crucial Role in Trastuzumab Clinical Efficacy | Q56989099 | ||
| Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization | Q74375151 | ||
| The "other" signaling of trastuzumab: antibodies are immunocompetent drugs | Q80888472 | ||
| Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy | Q81038993 | ||
| HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases | Q81643212 | ||
| Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic | Q89648608 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells | Q28282744 | ||
| Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor | Q29542169 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis. | Q30544833 | ||
| Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes | Q33642507 | ||
| An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation | Q33733313 | ||
| The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity | Q34073138 | ||
| HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment | Q34111958 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase | Q34323951 | ||
| Geldanamycin selectively targets the nascent form of ERBB3 for degradation | Q34427505 | ||
| Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients | Q34621219 | ||
| Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase | Q34720797 | ||
| Immune effects of trastuzumab | Q35057976 | ||
| Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa | Q35212601 | ||
| Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer | Q35780315 | ||
| (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease | Q35815494 | ||
| Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation | Q35889621 | ||
| Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum | Q35890128 | ||
| Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors | Q36542476 | ||
| A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy | Q36924491 | ||
| HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. | Q36957145 | ||
| Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells | Q36962681 | ||
| The development of HKI-272 and related compounds for the treatment of cancer | Q37169290 | ||
| Structure-based view of epidermal growth factor receptor regulation | Q37197992 | ||
| Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. | Q38098973 | ||
| Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial | Q38393636 | ||
| Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer | Q38743961 | ||
| Development of anti-HER2 fragment antibody conjugated to iron oxide nanoparticles for in vivo HER2-targeted photoacoustic tumor imaging. | Q38846962 | ||
| Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. | Q39085623 | ||
| Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification | Q39344908 | ||
| Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. | Q39411619 | ||
| A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines | Q39428554 | ||
| Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines | Q39820639 | ||
| Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab | Q39840667 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 808-811 | |
| P577 | publication date | 2018-01-30 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Targeting HER2 by Combination Therapies | |
| P478 | volume | 36 |
Search more.